Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 in Moderate to Severe Atopic Dermatitis
NCT07015762Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3002 in atopic dermatitis (AD) (6 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Safety and Tolerability of Multiple Doses of IBI3002. Started Jul 2025; status: recruiting.
02
Drugs
IBI3002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07015762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015762.